» Articles » PMID: 8669886

N-myc Protein Expression in Human Breast Carcinoma: Prognostic Implications

Overview
Journal Anticancer Res
Specialty Oncology
Date 1995 Nov 1
PMID 8669886
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The overexpression of N-myc gene and its protein products has been thought to be limited to cases of neuroblastoma, retinoblastoma and small cell lung carcinoma, but there is increasing evidence of its wider distribution in human tumors. This study showed that the protein of N-myc gene is associated in normal, benign and malignant human breast tissues. We found that N-myc oncoprotein is overexpressed in most breast carcinomas and that N-myc overexpression is significantly correlated with clinical stage, and histological grading of the tumors, and, more importantly with the clinical outcome of the patients. Analysis of DNA, mRNA and protein levels suggested that the high N-myc expression in breast cancer occurs without concomitant gene amplification. The finding of a direct inverse correlation between N-myc overexpression and the prognosis of patients with breast carcinoma suggests that N-myc expression may be useful as a prognostic factor in human breast cancer.

Citing Articles

Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.


Alterations and Co-Occurrence of C-MYC, N-MYC, and L-MYC Expression are Related to Clinical Outcomes in Various Cancers.

Lee M, Seok J, Saha S, Cho S, Jeong Y, Gil M Int J Stem Cells. 2023; 16(2):215-233.

PMID: 37105559 PMC: 10226856. DOI: 10.15283/ijsc22188.


Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin-induced apoptosis in epithelial ovarian cancer.

Yu R, Zhang H, Wang R, Xiao L Oncol Lett. 2022; 24(6):423.

PMID: 36284653 PMC: 9580255. DOI: 10.3892/ol.2022.13543.


Targeting in Pediatric and Adult Cancers.

Liu Z, Chen S, Clarke S, Veschi V, Thiele C Front Oncol. 2021; 10:623679.

PMID: 33628735 PMC: 7898977. DOI: 10.3389/fonc.2020.623679.


Molecular Mechanisms of Dysregulation in Cancers.

Liu R, Shi P, Wang Z, Yuan C, Cui H Front Oncol. 2021; 10:625332.

PMID: 33614505 PMC: 7886978. DOI: 10.3389/fonc.2020.625332.